Stonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling 38,597 shares worth $2.52 million in Q3. Despite ANI's strong fundamentals—with Q3 revenue surging 54% YoY to $227.8 million and stock up 49% over the past year—the fund's exit appears to be a portfolio rebalancing move toward earlier-stage biotech rather than a loss of confidence. ANI's future returns will depend on sustained rare disease growth and margin discipline rather than multiple expansion.

The global plasma derived medicine market is projected to grow from $17.24 billion in 2024 to $37.4 billion by 2034, driven by increasing demand for therapies treating rare and immune disorders, with North America currently dominating the market.

ADMA Biologics will report its second quarter 2025 financial results on August 6, 2025, after market close, with a conference call to discuss financial performance and company updates.

Several mid-cap medical and biotechnology stocks have outperformed the broader market in 2025, including Penumbra Inc, TransMedics Group Inc, and ADMA Biologics Inc. These companies have shown strong momentum, bullish analyst sentiment, and potential for continued upside.

ADMA Biologics, a U.S.-based biopharmaceutical company, has reiterated its strategic advantage through fully domestic manufacturing, commercialization, and supply chain operations. The company's vertically integrated U.S.-based infrastructure ensures supply chain robustness, regulatory compliance, and alignment with federal and private sector preferences for U.S.-made products.

ADMA Biologics, Inc. is being investigated by Block & Leviton for potential securities law violations following a delay in filing its Form 10-K and an ongoing audit by KPMG focused on evaluating internal controls.

ADMA Biologics, a biopharmaceutical company, saw its stock plummet 20% after the surprise resignation of its independent outside auditor. BFA Law is investigating the company for potential securities fraud.

ADMA Biologics, a biopharmaceutical company, is under investigation for potential securities fraud after its independent auditor unexpectedly resigned, causing a significant drop in the company's stock price.

ADMA Biologics, a biopharmaceutical company, disclosed the surprise resignation of its independent auditor, causing a significant drop in its stock price. A securities fraud investigation has been launched, and investors who lost money are encouraged to contact the law firm Bleichmar Fonti & Auld LLP.

ADMA Biologics is under investigation by Block & Leviton for potential securities law violations, following the resignation of the company's independent auditor. Investors who have lost money on their ADMA Biologics investment may be eligible to recover those losses.

ADMA Biologics Inc disclosed the abrupt resignation of its independent outside auditor CohnReznick LLP, causing a 16.33% drop in its stock price. Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ADMA Biologics investors.

The biopharmaceuticals contract manufacturing market is expected to grow at a steady CAGR due to the increasing prevalence of chronic diseases, growing R&D investments in biologics and biosimilars, and the rise in outsourcing by biopharma giants to streamline drug development.